Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DHG Pharmaceutical JSCSTC:DHG +1.26%80 Equity-to-Asset is 0.68 as of Jun. 2026, which is 9% below its 10-year median of 0.75. GuruFocus rates STC:DHG with a GF Score™ of 80/100 and a GF Value™ of ₫113,164.98 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,005 Drug Manufacturers companies, DHG Pharmaceutical JSC ranks better than 62.19% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
DHG Pharmaceutical JSC Equity-to-Asset Related Terms
DHG Pharmaceutical JSC Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for DHG Pharmaceutical JSC's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, DHG Pharmaceutical JSC's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DHG Pharmaceutical JSC Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DHG Pharmaceutical JSC's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where DHG Pharmaceutical JSC's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
DHG Pharmaceutical JSC's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHG Pharmaceutical JSC (STC:DHG) has a Equity-to-Asset of 0.68 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on DHG Pharmaceutical JSC and its competitors. This is near median its historical median of 0.75. Over the past decade, DHG Pharmaceutical JSC's Equity-to-Asset has ranged from 0.67 to 0.85. According to the industry distribution chart, DHG Pharmaceutical JSC ranks #380 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 37.8%.
Is DHG Pharmaceutical JSC's Equity-to-Asset too high?
DHG Pharmaceutical JSC's current Equity-to-Asset of 0.68 is near median its 10-year median of 0.75. Over the past 10 years, this metric has ranged from a low of 0.67 to a high of 0.85. The Drug Manufacturers industry median Equity-to-Asset is 0.60. DHG Pharmaceutical JSC's value of 0.68 is 13.3% above this industry median. Based on the distribution chart, DHG Pharmaceutical JSC ranks #380 out of 1005 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, DHG Pharmaceutical JSC has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DHG Pharmaceutical JSC's Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, DHG Pharmaceutical JSC ranks #380 out of 1005 companies for Equity-to-Asset. This puts DHG Pharmaceutical JSC in the upper half of its industry. The industry median Equity-to-Asset is 0.60. DHG Pharmaceutical JSC's value of 0.68 is 13.3% above this benchmark. Historically, DHG Pharmaceutical JSC's own Equity-to-Asset has ranged from 0.67 to 0.85 over the past decade. While the company's 10-year median is 0.75 vs. the industry median of 0.60, DHG Pharmaceutical JSC has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DHG Pharmaceutical JSC's current Equity-to-Asset of 0.68 is 13.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on DHG Pharmaceutical JSC and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DHG Pharmaceutical JSC's current Equity-to-Asset is 0.68, which is near median its own 10-year median of 0.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DHG Pharmaceutical JSC stock overvalued right now?
Based on GuruFocus' analysis, DHG Pharmaceutical JSC (STC:DHG) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫113,164.98, compared to a current price of ₫96,100.00 — trading 15.1% below its estimated fair value. The current Equity-to-Asset is 0.68, which is near median its 10-year median of 0.75 and 13.3% above the Drug Manufacturers industry median of 0.60. DHG Pharmaceutical JSC's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For DHG Pharmaceutical JSC (STC:DHG), the current Equity-to-Asset is 0.68 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DHG Pharmaceutical JSC (STC:DHG) Overvalued in 2026?
Based on GuruFocus' analysis, DHG Pharmaceutical JSC stock appears to be undervalued.
The current stock price of ₫96,100.00 is trading 15.1% below its estimated GF Value™ of ₫113,164.98.
GuruFocus considers DHG Pharmaceutical JSC to be Modestly Undervalued.
Key valuation signals for STC:DHG:
Equity-to-Asset: 0.68 (near median its 10-year median of 0.75)
GF Value™: ₫113,164.98 vs. price of ₫96,100.00 (15.1% below fair value)
Industry Position: 13.3% above the Drug Manufacturers median (#380 of 1005)
No single metric tells the full story. See the STC:DHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DHG Pharmaceutical JSC produces and trades in pharmaceutical products. It provides various pharmaceutical products in the areas of antibiotics, antifungals, and antiparasitics; analgesics and antipyretics; ear-nose-throat, cough, and asthma; ophthalmic and nervous system; muscular and osteoarticular; digestive; hepatic; cardiovascular and diabetic; vitamins and minerals; and dermal and beauty care.
80GF Score
Get the complete analysis for STC:DHG
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:DHG has been successfully added to your 
